Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what information his Department holds on the number of de-transitioners reporting harm from puberty blockers; and whether his Department considered this data as part of its approval of the trial.

There is currently no registry in place in the United Kingdom that routinely collects data that is specific to individuals who choose to detransition at any point following a previous medical intervention for gender reassignment.

Last month, NHS England published a Call for Evidence aimed at healthcare professionals and medical bodies to gather evidence on the care needs of individuals who choose to detransition, in line with the recommendations of the Cass Review. NHS England will publish plans for the establishment of a clinical detransition pathway in 2026, informed by the outcome of the Call for Evidence and a review of the published evidence.

The PATHWAYS trial has been subject to extensive scientific, clinical, ethical, and regulatory approvals. It was approved by an independent National Institute for Health and Care Research funding committee, with the final protocols all subject to rigorous approval processes from both the Medicines and Healthcare products Regulatory Agency and the Health Research Authority, including review by an independent Research Ethics Committee.